HC Wainwright Reaffirms Buy Rating for ASLAN PHARMACEU/ADR (ASLN)

Share on StockTwits

ASLAN PHARMACEU/ADR (NASDAQ:ASLN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday, The Fly reports. They presently have a $8.50 target price on the stock, down from their previous target price of $12.00. HC Wainwright’s target price suggests a potential upside of 139.44% from the company’s current price.

Separately, Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “sell” rating in a research report on Thursday, September 20th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $10.06.

Shares of ASLN stock opened at $3.55 on Monday. ASLAN PHARMACEU/ADR has a 52-week low of $2.51 and a 52-week high of $10.44.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.27. Research analysts forecast that ASLAN PHARMACEU/ADR will post -1.41 EPS for the current fiscal year.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China.

Further Reading: How Investors Use a Balance Sheet

The Fly

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply